Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Article from MarketBeat.com 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go hand in hand. Nevertheless, if you're considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and have no commercially available drugs or therapeutics. That status also means negative earnings (they are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage program. Do you own the worst stock of 2026? [Name + Ticker]
He issued warnings for RNG before it crashed 89%, BYND before it crashed 90%, TDOC before it crashed 84%, and FVRR before it crashed 86%. Now, he's stepping forward to name the popular stock that could go down as one of the worst-performing tickers of the year. It's could be the most dangerous stock of 2026. Click here for its name and ticker, 100% free. Even if a product advances through trials, profitability can still be years away. Only after reaching that milestone do companies typically receive the analyst coverage that attracts institutional investment. However, getting in on one of these medical stocks early and having it succeed can be transformative. Investors can see 3x, 5x, or even 10x returns. Many others, of course, never pan out—so investors interested in penny stocks often spread a lump sum across multiple biotech names. If it's a numbers game, diversification can be an effective approach. With that in mind, here are two small-cap biotech stocks that carry significant risks but could offer outsized rewards. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed has a commercially available product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany's leading digital health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. Mainz Biomed is also in early development of a non-invasive, blood-based screening test for pancreatic cancer and reported positive topline results from a feasibility study in October. That program, however, remains years from potential approval and commercialization. The risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains limited. The company included "Going Concern" language in its Sept. 26 SEC filing and subsequently filed a $150 million mixed shelf offering. That offering, for now, helps keep MYNZ above $1 and away from a delisting notice. Mainz Biomed is racing to generate enough revenue to change its financial trajectory. If it succeeds, even a modest investment could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive antiviral approach, but it also carries the financial risks typical of speculative small-caps. The company is developing a novel class of antiviral therapies based on its proprietary "nanoviricide" platform. These candidates are designed to mimic human cell surfaces, luring viruses to bind with them and thereby neutralizing pathogens before they can infect real cells. It's an innovative concept that, if validated in human trials, could represent a new paradigm in infectious disease treatment. NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. As with many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to advance programs. Recent filings indicate limited cash on hand, so investors should expect potential dilution. Still, if one candidate advances successfully into clinical development, the valuation upside could be significant. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
